| Document |
Document Title |
|
WO/2021/228253A1 |
Disclosed are an IL-2 mutant, a fusion protein or conjugate comprising the IL-2 mutant, and a pharmaceutical composition comprising the IL-2 mutant, fusion protein or conjugate. Compared with wild-type IL-2, the IL-2 mutant has reduced b...
|
|
WO/2021/229297A1 |
Methods to extract chlorella protein from algae powder are described. A first extraction method is an alkaline solution extraction method. A second extraction method is an enzyme extraction method. A third method is a low-temperature dee...
|
|
WO/2021/223422A1 |
Provided is an anti-HIV polypeptide modified with polyethylene glycol (PEG). Specifically, cysteine is added to the N-terminus, C-terminus, or position 10 of a C34 polypeptide, and the C34 polypeptide is subjected to a Michael addition r...
|
|
WO/2021/223048A1 |
Provided are an anti-CD20 antibody-drug conjugate, a preparation comprising the antibody-drug conjugate, a composition comprising the antibody-drug conjugate, and a pharmaceutical use of the antibody-drug conjugate.
|
|
WO/2021/224833A1 |
The present invention relates to a bio-nanocompound including: metal oxide particles as a substrate; an amino organosilane as a bonding agent; a dialdehyde as a cross-linking agent; and a nucleating agent that uses the nucleating activit...
|
|
WO/2021/224680A1 |
Compounds that are mammalian metabolites of an agonist of G-protein-coupled receptor 1.39 (GPR139), intermediates used in the synthesis of such metabolites, pharmaceutical compositions comprising such metabolites, and the use of such met...
|
|
WO/2021/226519A1 |
Compounds of Formula la, lb, or Ic, are described, where the various substituents are defined herein. The compounds can modulate a property or effect of Akt3 in vitro or in vivo, and can also be used, individually or in combination with ...
|
|
WO/2021/226517A1 |
Compounds of Formula la, lb, or Ic,, are described, where the various substituents are defined herein. The compounds can modulate a property or effect of Akt3 in vitro or in vivo, and can also be used, individually or in combination with...
|
|
WO/2021/226247A1 |
The present disclosure provides for bioconjugation of biomolecules with functionalized trans-cyclooctenes (TCOs).
|
|
WO/2021/226351A1 |
A method includes receiving one input feature and one output feature of importance of polymers used to stabilize a protein. A set of polymers from a library are identified based on the input feature and the output feature of importance t...
|
|
WO/2021/223346A1 |
An application of a yam protein extract in preparation of a medication for treating erectile dysfunction. The yam protein extract is prepared by means of the following modes: homogenizing fresh yam with distilled water in an amount of 8-...
|
|
WO/2021/224631A1 |
A carrier system (100) provides a carrier or carriers (12) for carrying assay samples in an assay. The carrier(s) are secured to a substrate (10) by a release layer (14). The carrier(s) are suitable for receiving an assay sample, and the...
|
|
WO/2021/223020A1 |
This application relates to an aqueous mixture composition to collect, transport and store samples suspected of containing a pathogen, the composition comprising a chaotropic agent, a chelator, a detergent, a buffer, and optionally an al...
|
|
WO/2021/221085A1 |
The purpose of the present invention is to provide a method for mass-producing individual imidazole dipeptides at high purity and on an industrial scale regardless of the kind of an animal extract. This purpose is achieved by a method fo...
|
|
WO/2021/218895A1 |
Provided in the present application are a bifunctional protein which can bind to PD-1 (programmed death receptor-1) and TGF-β (transforming growth factor-β), the medical use of the bifunctional protein, and a preparation method therefor.
|
|
WO/2021/222120A1 |
Disclosed are methods for purifying antibodies using a Protein A Chromatography Column and an arginine wash, resulting in decreased host cell protein (HCP) contamination. The method may comprise loading a composition comprising an antibo...
|
|
WO/2021/217252A1 |
Methods are provided for determining the presence of antibodies in blood or a blood product, using immobilized self-assembled polypeptides comprising an ectodomain and being recognized by the antibodies. The self-assembled polypeptide co...
|
|
WO/2021/221783A1 |
The disclosure features chimeric antigen receptor (CAR) ligands, methods for making the same, and immunomodulatory compositions comprising the CAR ligands. The disclosure also features compositions and methods of using the immunomodulato...
|
|
WO/2021/217251A1 |
Surfaces and processes are provided for immobilization of multimer polypeptides that preserves the functionality and active conformation of the native multimeric polypeptides. The multimer polypeptide is a self-assembled multimer and com...
|
|
WO/2021/222735A1 |
Provided herein is a column-based continuous viral inactivation system, comprising one or both of a pH feedback controller to adjust feed flow rates and a minimum residence time (MRT) feedback controller to adjust feed flow rates. Method...
|
|
WO/2021/220252A1 |
A process for purification of antibody or fusion protein through anion exchange chromatography to produce an antibody or fusion protein which is substantially free of at least one of the product-related impurities.
|
|
WO/2021/220251A1 |
The invention provides a process of purification of antibody or fusion protein from protein mixture comprising product and process related impurities. The process provides the use of hydroxyapatite chromatography for the separation of lo...
|
|
WO/2021/221485A1 |
The present invention relates to a human interferon-beta variant with double mutation and a method for improving stability of a human interferon-beta variant and, more specifically, to a human interferon-beta variant including an amino a...
|
|
WO/2021/221130A1 |
The present invention addresses the problem of providing, inter alia, a method for searching for protein refolding conditions, the method making it possible to efficiently search for refolding conditions that yield excellent refolding re...
|
|
WO/2021/220500A1 |
[Problem] The purpose of the present invention is to suppress variation in the elution position of a compound due to the influence of a preservation solution in purification of a compound that has a charged portion without performing a s...
|
|
WO/2021/212220A1 |
Isolated, pure, soluble isoform free recombinant human interferon alpha 2b (rhIFN α-2b). Methods of making the soluble isoform free rhIFN α-2b. Stable compositions and formulations of isoform free rhIFN α-2b are for administration gen...
|
|
WO/2021/216635A1 |
In a method for facilitating selection of chromatography parameters for manufacturing a therapeutic protein, one or more process parameter values associated with a hypothetical chromatography process, and one or more molecular descriptor...
|
|
WO/2021/212755A1 |
Provided is an anti-novel coronavirus antibody. The antibody is a specific antibody extracted from chicken egg yolk. Also provided is an auxiliary drug using the anti-novel coronavirus antibody as a main component for preventing and cont...
|
|
WO/2021/209072A1 |
Provided in the present invention is an aerolysin nanochannel-based method for protein/polypeptide sequencing, enabling accurate acquisition of natural amino acids and post-translation-modified, specific-resolution, and monomolecular pro...
|
|
WO/2021/207833A1 |
A method of preserving one or more chemical and/or biological species in a polymer matrix comprising pullulan and trehalose is described. The method includes combining the one or more chemical and/or biological species, an aqueous pullul...
|
|
WO/2021/210662A1 |
The present invention addresses the problem of providing: a method for removing color from an active ingredient solution for a protein formulation, particularly, an antibody formulation; a production method that is for an active ingredie...
|
|
WO/2021/211059A1 |
The present disclosure relates to a method of forming a keratin filament network, comprising: (i) dialysing a solubilized keratin solution in a dialysis buffer solution at a pH of about 2.5 to about 5.5 to obtain purified keratin; (ii) m...
|
|
WO/2021/208818A1 |
Provided are a phosphorylated protein labeling reagent containing equal-weight stable isotopes, a preparation method therefor and a use thereof. The protein labeling reagent is a phosphorylated dipeptide organophosphorus reagent labeled ...
|
|
WO/2021/208839A1 |
Provided is a process of purifying a bispecific antibody comprising a TCR constant domain from a fluid comprising said bispecific antibody and potential impurities, wherein said process comprises subjecting said fluid to a Protein A chro...
|
|
WO/2021/207870A1 |
The present invention provides a method for preparing atosiban, comprising the following steps: (a) by using a Fmoc-Gly-Rink resin as a carrier, coupling amino acids having N-terminuses protected by Fmoc one by one to the Fmoc-Gly-Rink r...
|
|
WO/2021/209851A1 |
Flow-through processes for purifying a target molecule (e.g., antibodies, enzymes, and hormones, particularly a monoclonal antibody) from a biological solution (e.g., a neutralized viral inactivation pool) in a sample that includes the t...
|
|
WO/2021/203864A1 |
Provided in the present invention are an incretin analogue, a preparation method therefor, and the use thereof. The incretin analogue has a GLP-1R/GIPR/GCGR agonist activity, is a triple agonist, and can be used for lowering blood glucos...
|
|
WO/2021/204170A1 |
Disclosed in the present invention are an active peptide derived from Eupolyphaga sinensis Walker and having a blood lipid lowering function, and a preparation method therefor and the use thereof. The active peptide of the present invent...
|
|
WO/2021/197248A1 |
A purification system and method used for continuous purification. The purification system comprises: (1) at least one affinity chromatography main unit, wherein each affinity chromatography main unit independently comprises one or more ...
|
|
WO/2021/197063A1 |
The present invention relates to the technical fields of rice wine lee resource utilization and blood pressure reduction, and particularly relates to an oligopeptide having a blood pressure reducing effect and a preparation method theref...
|
|
WO/2021/197249A1 |
A system for continuous purification of biopharmaceutical products in the field of biopharmaceutical. The system controls the start and stop of a purification link by means of the monitoring of a sensor, enables the whole purification pr...
|
|
WO/2021/201405A1 |
The present invention relates to a fusion protein of the Z-domain and calsequestrin, having improved reactivity, stability, and antibody recovery, and a method for isolation and purification of an antibody using same. Specifically, the p...
|
|
WO/2021/201087A1 |
Multispecific antigen-binding molecule capable of binding to multiple different antigens, but do not non-specifically crosslink two or more immune cells such as T cells are provided. Methods for producing or enriching a preferred structu...
|
|
WO/2021/197051A1 |
Disclosed is a method for efficiently separating and purifying recombinant human coagulate factor VIII Fc fusion protein. The method comprises steps of affinity chromatography and anion exchange chromatography; and the sample captured by...
|
|
WO/2021/202183A1 |
The present invention is directed to Fc fusion water soluble GPCR (G-protein coupled receptor) proteins with QTY membrane regions, wherein the amino acids Q (Glutamine), T (Threonine), and Y (Tyrosine), together with other amino acids ca...
|
|
WO/2021/194910A1 |
There is disclosed compositions and methods for treating and preventing Acute Respiratory Distress Syndrome (ARDS) including ARDS caused by viral respiratory disease of zoonotic origin such as eoronaviruses. The present disclosure is bas...
|
|
WO/2021/193553A1 |
Provided is a method for producing trimeric and tetrameric IgA antibodies, the method including mixing dimeric IgA antibodies and monomeric IgA antibodies.
|
|
WO/2021/191253A1 |
The present invention provides methods for producing a heme pe- roxidase from inclusion bodies (IBs) comprising the steps of: providing the heme peroxidase in the form of IBs, solubilizing said IBs, transferring said solubilized IBs into...
|
|
WO/2021/191194A1 |
The present disclosure relates to methods of protein purification by attaching an intein-C fragment to a target protein, passing a sample containing the intein-C tagged protein over a chromatographic resin carrying an intein-N fragment s...
|
|
WO/2021/189604A1 |
Provided are a method for preparing a sea cucumber protein peptide, and the use thereof. The preparation method comprises removing the viscera from fresh Iceland Red Ginseng, washing same and air-drying same, grinding same into a homogen...
|
